References
- 1. W. C. Stanley and M. Marzilli, Metabolic therapy in the treatment of ischaemic heart disease: The pharmacology of trimetazidine, Fundam. Clin. Pharmacol.17 (2003) 133–145; https://doi.org/10.1046/j.1472-8206.2003.00154.x
- 2. P. Chrusciel, J. Rysz and M. Banach, Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease, Drugs74 (2014) 971–980; https://doi.org/10.1007/s40265-014-0233-5
- 3. European Medicines Agency, European Medicines Agency recommends restricting use of trimetazidine-containing medicines, EMA/CHMP/417861/2012; EMA, London 2012, https://www.ema.europa.eu/documents/press-release/european-medicines-agency-recommends-restricting-use-trimetazi-dine-containing-medicines_en.pdf; last access date August 31, 2018.
- 4. Z. Liu, J. M. Chen, H. Huang, M. Kuznicki, S. Zheng, W. Sun, N. Quan, L. Wang, H. Yang, H. M. Guo, J. Li and J. Zhuang, The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway, Metabolism65 (2016) 122–130; https://doi.org/10.1016/j.metabol.2015.10.022
- 5. A. Onay-Besikci and S. A. Özkan, Trimetazidine revisited: A comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine, Cardiovasc. Ther.26 (2008) 147–165; https://doi.org/10.1111/j.1527-3466.2008.00043.x
- 6. T. K. Murthy, G. D. Sankar and S. R. Yarraguntla, Visible spectrophotometric methods for the determination of trimetazidine dihydrochloride in pharmaceutical formulations, Indian Drugs39 (2002) 230–233.
- 7. A. A. Chiş, F. G. Gligor, G. Cormoş, E. Curea and M. Bojiţă, Spectrophotometric method for the determination of amorolfine, Farmacia58 (2010) 629–636.
- 8. S. O. Thoppil, R. M. Cardoza and P. D. Amin, Stability indicating HPTLC determination of trimetazidine as bulk drug and in pharmaceutical formulations, J. Pharm. Biomed. Anal.25 (2001) 15–20; https://doi.org/10.1016/S0731-7085(00)00440-4
- 9. L. I. Bebawy, M. F. El Tarras and S. A. El Sabour, Determination of trimetazidine dihydrochloride in the presence of its acid-induced degradation products, J. AOAC Int.87 (2004) 827–833.
- 10. M. Gackowski, M. Koba and K. Mądra-Gackowska, Determination of lormetazepam in tablets using high-performance liquid chromatography, and derivative spectrophotometry methods, J. Planar Chromatogr. - Mod. TLC31 (2018) 235–242; https://doi.org/10.1556/1006.2018.31.3.9
- 11. M. Gackowski, M. Koba and S. Kruszewski, Comparison of UV- and derivative-spectrophotometric and HPTLC UV-densitometric methods for the determination of amrinone and milrinone in bulk drugs, Curr. Pharm. Anal.14 (2018) 1–8; https://doi.org/10.2174/1573412914666180627141659
- 12. AOAC International, Guidelines for Standard Method Performance Requirements (Appendix F), AOAC Off. Methods Anal; AOAC Int. 2016, http://www.eoma.aoac.org/app_f.pdf; https://doi.org/10.13140/RG.2.2.20883.89125, access date August 31, 2018.
- 13. P. Rashmin, P. Mrunali, D. Nitin, D. Nidhi and P. Bharat, HPTLC method development and validation: Strategy to minimize methodological failures, J. Food Drug Anal.20 (2012) 794–804; https://doi.org/10.6227/jfda.2012200408
- 14. M. Koba, K. Koba and T. Bączek, Determination of oxazepam in pharmaceutical formulation by HPTLC UV-densitometric and UV-derivative spectrophotometry methods, Anal. Lett.42 (2009) 1831–1843; https://doi.org/10.1080/00032710903060719
- 15. B. Spangenberg, Does the Kubelka-Munk theory describe TLC evaluations correctly?, J. Planar Chromatogr. – Mod. TLC19 (2006) 332–341; https://doi.org/10.1556/JPC.19.2006.5.1